122 related articles for article (PubMed ID: 9354673)
1. Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma.
Ristamäki R; Joensuu H; Lappalainen K; Teerenhovi L; Jalkanen S
Blood; 1997 Nov; 90(10):4039-45. PubMed ID: 9354673
[TBL] [Abstract][Full Text] [Related]
2. Serum CD44 in non-Hodgkin's lymphoma.
Ristamäki R; Joensuu H; Jalkanen S
Leuk Lymphoma; 1999 May; 33(5-6):433-40. PubMed ID: 10342571
[TBL] [Abstract][Full Text] [Related]
3. Serum CD44 levels preceding the diagnosis of non-Hodgkin's lymphoma.
Mäenpää H; Ristamäki R; Virtamo J; Franssila K; Albanes D; Joensuu H
Leuk Lymphoma; 2000 May; 37(5-6):585-92. PubMed ID: 11042519
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of circulating CD44 in non-Hodgkin's lymphoma.
Ristamäki R; Joensuu H; Hagberg H; Kalkner KM; Jalkanen S
Int J Cancer; 1998 Jun; 79(3):221-5. PubMed ID: 9645341
[TBL] [Abstract][Full Text] [Related]
5. High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Iijima K
Leuk Res; 2002 Mar; 26(3):241-8. PubMed ID: 11792412
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma.
Sasaki K; Niitsu N
Eur J Haematol; 2000 Sep; 65(3):195-202. PubMed ID: 11007056
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of soluble CD44 in patients with breast and colorectal carcinomas and non-Hodgkin's lymphoma.
Lockhart MS; Waldner C; Mongini C; Gravisaco MJ; Casanova S; Alvarez E; Hajos S
Oncol Rep; 1999; 6(5):1129-33. PubMed ID: 10425314
[TBL] [Abstract][Full Text] [Related]
8. Serum levels and differential expression of CD44 in childhood leukemia and malignant lymphoma: correlation with prognostic criteria and survival.
Taçyildiz N; Cavdar AO; Yavuz G; Gözdaşoglu S; Unal E; Ertem U; Duru F; Ikinciogullari A; Babacan E; Kuzu I; Cin S
Pediatr Int; 2001 Aug; 43(4):354-60. PubMed ID: 11472578
[TBL] [Abstract][Full Text] [Related]
9. Serum osteopontin and CD44 levels in lymphoreticular malignancies in children.
Elli M; Dagdemir A; Bozkurt C; Pinarli FG; Duzgun A; Ozmen ZC; Ertem U; Acar S
Bratisl Lek Listy; 2012; 113(9):534-8. PubMed ID: 22979908
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas.
Shah N; Cabanillas F; McIntyre B; Feng L; McLaughlin P; Rodriguez MA; Romaguera J; Younes A; Hagemeister FB; Kwak L; Fayad L
Leuk Lymphoma; 2012 Jan; 53(1):50-6. PubMed ID: 21895545
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Rotnakkarin P; Sutcharitchan P; Wannagrairoj P
Clin Lymphoma; 2003 Jun; 4(1):52-5. PubMed ID: 12837156
[TBL] [Abstract][Full Text] [Related]
12. Validation of the international prognostic index in working formulation group A low-grade non-Hodgkin's lymphoma: retrospective analysis of 137 patients from the Gruppo Italiano per lo Studio dei Linfomi registry.
Stelitano C; Baldini L; Pieresca C; Callea V; Angrilli F; Clò V; Partesotti G; Merli F; Cavanna L; Morabito F; Federico M; Brugiatelli M; Silingardi V
Haematologica; 2000 Feb; 85(2):154-9. PubMed ID: 10681722
[TBL] [Abstract][Full Text] [Related]
13. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
14. [Primary gastrointestinal non-Hodgkin's lymphoma in two Hungarian regions].
Kollár B; Rajnics P; Hunyady B; Zeleznik E; Jakucs J; Egyed M
Orv Hetil; 2009 Aug; 150(35):1649-53. PubMed ID: 19692309
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of CA 125 in patients with non-Hodgkin's lymphoma.
Zacharos ID; Efstathiou SP; Petreli E; Georgiou G; Tsioulos DI; Mastorantonakis SE; Christakopoulou I; Roussou PP
Eur J Haematol; 2002 Oct; 69(4):221-6. PubMed ID: 12431241
[TBL] [Abstract][Full Text] [Related]
16. Non-Hodgkin's lymphomas: immunologic prognostic studies.
Hadzi-Pecova L; Petrusevska G; Stojanovic A
Prilozi; 2007 Jul; 28(1):39-55. PubMed ID: 17921917
[TBL] [Abstract][Full Text] [Related]
17. Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diffuse large B-cell lymphoma: association with clinical characteristics and outcome.
Terol MJ; Tormo M; Martinez-Climent JA; Marugan I; Benet I; Ferrandez A; Teruel A; Ferrer R; García-Conde J
Ann Oncol; 2003 Mar; 14(3):467-74. PubMed ID: 12598355
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
[TBL] [Abstract][Full Text] [Related]
19. A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Sasaki K; Umeda M
Leukemia; 1999 Sep; 13(9):1434-40. PubMed ID: 10482996
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.
Jabbour E; Peslin N; Arnaud P; Ferme C; Carde P; Vantelon JM; Bocaccio C; Bourhis JH; Koscielny S; Ribrag V
Leuk Lymphoma; 2005 Jun; 46(6):861-7. PubMed ID: 16019530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
